Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 4/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | LDHA | P00338 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 3/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | EDNRB | P24530 | 3/20 | 0.34 |
| ▸ | EDNRA | P25101 | 3/20 | 0.34 |
| ▸ | PPARD | Q03181 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1025381 | 0.80 | ALDH1A1 (0.36) | PPARGNR1I2AGTR2MEN1BLM | |
| SCHEMBL2104209 | 0.80 | TSHR (0.46) | PPARGMEN1KMT2APPARAEDNRB | |
| SCHEMBL1371338 | 0.76 | KMT2A (0.40) | PPARGNR1I2KMT2APPARAEDNRB | |
| SCHEMBL1025798 | 0.76 | MEN1 (0.41) | MEN1KMT2AALDH1A1 | |
| SCHEMBL4977225 | 0.72 | PTGDR2 (0.54) | MEN1KMT2AFFAR1 | |
| SCHEMBL22462124 | 0.71 | AKT1 (0.55) | PPARGNR1I2AGTR2MEN1BLM | |
| Iodide SCHEMBL5967764 | 0.70 | PTGDR2 (0.52) | MEN1KMT2AFFAR1 | |
| Iodide SCHEMBL5967765 | 0.70 | PTGDR2 (0.52) | MEN1KMT2AFFAR1 | |
| SCHEMBL11104758 | 0.69 | PPARA (0.42) | PPARGAKR1C3AKR1C2LDHAPPARA | |
| SCHEMBL3397535 | 0.69 | EDNRB (0.40) | MEN1BLMKMT2AAKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060211765-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211765-A1 | Novel compounds | ADRA2C, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCAR2 | PPARG 30/4885NR1I2 774/4885AGTR2 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.